Get started
bioMerieux SAbioMerieux SAbioMerieux SA

bioMerieux SA

No trades
See on Supercharts
OverviewFinancialsNewsIdeasDiscussionsTechnicalsForecastSeasonalsBondsETFs

BIM chart


Full chart

BIM upcoming earnings


Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—

Key stats


Market capitalization
‪13.36 B‬ EUR
Dividend yield (indicated)
0.80%
Price to earnings Ratio (TTM)
35.3
Basic EPS (TTM)
3.2 EUR
Net income (FY)
‪432.20 M‬ EUR
Revenue (FY)
‪3.98 B‬ EUR
Shares float
‪41.33 M‬
Beta (1Y)
0.53

Employees


Employees (FY)
‪14.75 K‬
Change (1Y)
+103 +0.70%
Revenue / Employee (1Y)
‪269.75 K‬ EUR
Net income / Employee (1Y)
‪29.29 K‬ EUR

About bioMerieux SA


Sector
Health Technology
Industry
Medical Specialties
CEO
Pierre Boulud
Website
biomerieux.com
Headquarters
Marcy l'Etoile
Founded
1967
ISIN
FR0013280286
FIGI
BBG00X8QLQY3
bioMérieux SA engages in the provision of in vitro diagnostic solutions, which determine the source of disease and contamination. It develops testing, detection, and other laboratory system for the analysis of cancer, diseases, and infections caused by bacteria, virus, and fungi. The company was founded Alain Mérieux in 1963 and is headquartered in Marcy l'Etoile, France.

Check out other big names from the same industry as BIM.

Financials


Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:—

BIM news



Technicals


Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Analyst rating


An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Seasonals


Displays a symbol's price movements over previous years to identify recurring trends.

BIM highest yielding bonds


BIMAC
bioMerieux SA 1.902% 29-JUN-2030
Yield to maturity
1.90%
Maturity date
Jun 29, 2030
BIMAB
bioMerieux SA 1.5% 29-JUN-2027
Yield to maturity
1.50%
Maturity date
Jun 29, 2027

See all BIM bonds 

Frequently Asked Questions


The current price of BIM is 113.4 EUR — it has increased by 0.18% in the past 24 hours. Watch bioMerieux SA stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on VIE exchange bioMerieux SA stocks are traded under the ticker BIM.
BIM stock has fallen by −1.75% compared to the previous week, the month change is a −5.31% fall, over the last year bioMerieux SA has showed a 4.61% increase.
We've gathered analysts' opinions on bioMerieux SA future price: according to them, BIM price has a max estimate of 140.00 EUR and a min estimate of 90.00 EUR. Watch BIM chart and read a more detailed bioMerieux SA stock forecast: see what analysts think of bioMerieux SA and suggest that you do with its stocks.
BIM reached its all-time high on Oct 12, 2020 with the price of 143.7 EUR, and its all-time low was 2.6 EUR and was reached on Jun 7, 2006. View more price dynamics on BIM chart.
See other stocks reaching their highest and lowest prices.
BIM stock is 1.24% volatile and has beta coefficient of 0.53. Track bioMerieux SA stock price on the chart and check out the list of the most volatile stocks — is bioMerieux SA there?
Today bioMerieux SA has the market capitalization of ‪13.34 B‬, it has decreased by −2.07% over the last week.
Yes, you can track bioMerieux SA financials in yearly and quarterly reports right on TradingView.
bioMerieux SA is going to release the next earnings report on Mar 4, 2026. Keep track of upcoming events with our Earnings Calendar.
BIM earnings for the last half-year are 1.35 EUR per share, whereas the estimation was 2.17 EUR, resulting in a −37.64% surprise. The estimated earnings for the next half-year are 2.06 EUR per share. See more details about bioMerieux SA earnings.
bioMerieux SA revenue for the last half-year amounts to ‪2.04 B‬ EUR, despite the estimated figure of ‪2.07 B‬ EUR. In the next half-year revenue is expected to reach ‪2.12 B‬ EUR.
BIM net income for the last half-year is ‪161.00 M‬ EUR, while the previous report showed ‪216.90 M‬ EUR of net income which accounts for −25.77% change. Track more bioMerieux SA financial stats to get the full picture.
Yes, BIM dividends are paid annually. The last dividend per share was 0.90 EUR. As of today, Dividend Yield (TTM)% is 0.80%. Tracking bioMerieux SA dividends might help you take more informed decisions.
bioMerieux SA dividend yield was 0.87% in 2024, and payout ratio reached 24.56%. The year before the numbers were 0.84% and 28.08% correspondingly. See high-dividend stocks and find more opportunities for your portfolio.
As of Sep 29, 2025, the company has ‪14.75 K‬ employees. See our rating of the largest employees — is bioMerieux SA on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. bioMerieux SA EBITDA is ‪961.60 M‬ EUR, and current EBITDA margin is 22.45%. See more stats in bioMerieux SA financial statements.
Like other stocks, BIM shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade bioMerieux SA stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So bioMerieux SA technincal analysis shows the sell today, and its 1 week rating is neutral. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating bioMerieux SA stock shows the buy signal. See more of bioMerieux SA technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.